Patents Examined by Pancham Bakshi
-
Patent number: 11980667Abstract: Trans-activating transcription (TAT) factor peptide oligomers coupled with functional agents can selectively complex to the anionic surface of cancerous cells. The TAT conjugates can be delivered to the locus of the tumors using intra-arterial injection during transient blood flow arrest.Type: GrantFiled: December 9, 2019Date of Patent: May 14, 2024Assignee: The Trustees of Columbia University in the City of New YorkInventor: Shailendra Joshi
-
Patent number: 11975976Abstract: A process for removing metallic impurities from halogenated silicon compounds, such as chlorosilane monomers and/or chlorinated polysilanes is disclosed. The process involves treating a halogenated silicon compound with a tertiary amine and thereafter a suitable grade of activated carbon.Type: GrantFiled: August 10, 2020Date of Patent: May 7, 2024Assignee: Dow Silicones CorporationInventors: Reza Hagh Panah, Michael Depierro, Barry Ketola
-
Patent number: 11970436Abstract: The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative. Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w). The purified monoterpene can be used to treat a disease such as cancer. The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.Type: GrantFiled: May 20, 2022Date of Patent: April 30, 2024Assignee: UNIVERSITY OF SOUTHERN CALIFORNIAInventors: Thomas Chen, Daniel Levin, Satish Puppali
-
Patent number: 11969437Abstract: The present invention provides a ready-to-use sterile alginate aqueous solution preparation which is packed in a sealed container or an airtight container and which has storage stability, comprising: (a) a low-endotoxin monovalent metal salt of alginic acid having a weight average molecular weight of 50,000 to 400,000 by a GPC-MALS method; (b) a salt selected from a monovalent metal salt and an ammonium salt; and (c) water, wherein a concentration of the component (a) is 1.5% by mass or more, a concentration of the component (b) is 0.5 to 2% by mass, and a viscosity measured at 20° C. using a rotational viscometer is 2700 mPa·s or more, and a method of producing the same. This alginate aqueous solution preparation is a ready-to-use aqueous solution preparation of a low-endotoxin monovalent metal salt of alginic acid.Type: GrantFiled: March 6, 2018Date of Patent: April 30, 2024Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.Inventors: Shuichi Endo, Motoi Nakahara
-
Patent number: 11965062Abstract: The method of preparing the polycarbonate ether polyol or high molecular weight polyether carbonate using controlled addition of materials during polymerisation includes the steps of: mixing catalyst of formula(I), double metal cyanide (DMC) catalyst and optionally carbon dioxide and/or solvent with epoxide and optionally starter compound and/or carbon dioxide; or mixing DMC catalyst and optionally starter compound, carbon dioxide and/or solvent with epoxide and optionally carbon dioxide and/or solvent; or mixing epoxide, catalyst of formula(I), starter compound and carbon dioxide and optionally solvent; or mixing catalyst of formula (I), DMC catalyst and optionally starter compound, epoxide, carbon dioxide and/or solvent to form in each case a mixture (?); and adding one or more of starter compound, epoxide, carbon dioxide, catalyst of formula(I), DMC catalyst and/or solvent to mixture (?) to form mixture (?) comprising starter compound, epoxide, carbon dioxide, catalyst of formula(I), DMC catalyst and optioType: GrantFiled: October 24, 2018Date of Patent: April 23, 2024Assignee: Econic Technologies LTD.Inventors: Michael Kember, James Leeland, Rakibul Kabir, Emmalina Hollis
-
Patent number: 11964023Abstract: The present invention provides capsular polysaccharides from Streptococcus pneumoniae serotypes identified using NMR. The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additional Steptococcus pneumoniae serotypes.Type: GrantFiled: June 24, 2022Date of Patent: April 23, 2024Assignee: Merck Sharp & Dohme LLCInventors: Richard J. Porambo, Chitrananda Abeygunawardana, Luwy Kavuka Musey, Michael J. Kosinski, Yadong Adam Cui
-
Patent number: 11957652Abstract: Compositions contain citrulline and leucine or a metabolite thereof, such as hydroxyisocaproic acid (HICA) or beta-hydroxy-beta-methylbutyrate (HMB), including, for example, a synergistic amount of citrulline and leucine. Such compositions may be used in methods for treatment of pre-diabetes, metabolic syndrome, or diabetes.Type: GrantFiled: July 22, 2022Date of Patent: April 16, 2024Assignee: Societe des Produits Nestle S.A.Inventors: Christophe Moinard, Gabrielle Ventura, Denis Breuille, Christian Darimont-Nicolau, Luc Cynober
-
Patent number: 11957650Abstract: A formulation and a method for treating, preventing or ameliorating or alleviating in a patient the symptoms of hangover, or veisalgia, associated with a bout of excessive alcohol consumption are disclosed. More specifically, a formulation comprising L-cysteine, thiamine and pyridoxine and a method for treating, preventing, ameliorating, or alleviating in a patient one or more of the symptoms of nausea, headache, diminished concentration, malaise and/or tiredness, and a desire to consume greasy and/or fatty and/or oily foods, associated with a bout of excessive alcohol consumption are disclosed.Type: GrantFiled: April 9, 2021Date of Patent: April 16, 2024Assignee: PHOENIX PHARMACEUTICALS AUSTRALIA PTY LTDInventors: Laurence Guy Howes, Jan Beatrice Quinton
-
Patent number: 11945825Abstract: The present invention encompasses the use of compounds for a novel approach to treat and prevent diseases, conditions, and disorders such as diabetes and ischemic reperfusion injury. Compounds of the invention, including but not limited to BAM15 ((2-fluorophenyl){6-[(2-fluorophenyl)amino](1,2,5-oxadiazolo[3,4-e]pyrazin-5-yl)}amine), a mitochondrial uncoupler, can improve glucose tolerance, increases cellular oxygen consumption, treat or prevent kidney ischemia reperfusion injury reverse insulin resistance, reverse or treat hyperinsulinemia, and reverse or treat hyperlipidemia. The present invention further provides novel compounds as well as methods for identifying compounds with the same or similar properties as BAM15.Type: GrantFiled: July 1, 2021Date of Patent: April 2, 2024Assignee: UNIVERSITY OF VIRGINIA PATENT FOUNDATIONInventors: Kyle Hoehn, Brandon Kenwood
-
Patent number: 11931373Abstract: Disclosed herein are compounds and methods for inhibiting Aha1 for the treatment of tauopathies and neurodegenerative diseases. The Aha1 inhibitor may reduce the interaction between Aha1 and Hsp90. The Aha1 inhibitor may reduce aggregation of tau protein. The Aha1 inhibitor may include a compound selected from KU-177, KU-174, and KU-308.Type: GrantFiled: April 15, 2022Date of Patent: March 19, 2024Assignees: University of South Florida, University of KansasInventors: Chad Dickey, Lindsey Shelton, Brian Blagg, John Koren, Laura Jenelle Blair
-
Patent number: 11925660Abstract: A treatment for obesity can include: providing a superabsorbent material that includes a porous network structure formed from a mixture of a plurality of water soluble polysaccharides that are not chemically crosslinked together; and administering the superabsorbent material to a subject in an effective amount to provide a treatment for obesity in the subject. The treatment can include at least one of: reducing weight of the subject; reducing rate of weight gain in the subject; or increasing rate of weight loss in the subject. The treatment of obesity can include at least one of: reducing caloric intake into the subject; reducing caloric absorption by the gut of the subject; absorbing caloric material from the gut of the subject into the superabsorbent material; or increasing transfer of caloric material from bloodstream into gut.Type: GrantFiled: May 21, 2021Date of Patent: March 12, 2024Inventor: Lijun Sun
-
Patent number: 11918602Abstract: Methods for reducing cholesterol in a subject can include: providing a superabsorbent material that includes a porous network structure formed from a mixture of a plurality of water soluble polysaccharides that are not chemically crosslinked together; and administering the superabsorbent material to a subject in an effective amount to reduce cholesterol in the subject. The reduction of cholesterol includes at least one of: reducing total cholesterol of the subject; reducing a rate of total cholesterol increase in the subject; or increasing a rate of total cholesterol decrease in the subject. The reduction of cholesterol includes at least one of: reducing cholesterol intake into the subject; reducing cholesterol absorption by the gut of the subject; or absorbing cholesterol material from the gut of the subject into the superabsorbent material. The reduction of cholesterol is by reduction of low-density-lipoprotein cholesterol or high-density-lipoprotein cholesterol.Type: GrantFiled: May 21, 2021Date of Patent: March 5, 2024Inventor: Lijun Sun
-
Patent number: 11919874Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R11a, R11b, R11c, R11d, and X, are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.Type: GrantFiled: August 17, 2021Date of Patent: March 5, 2024Assignees: The University of British Columbia, Provincial Health Services AuthorityInventors: Raymond J. Andersen, Marianne Dorothy Sadar, Kunzhong Jian, Nasrin R. Mawji, Jun Wang, Carmen Adriana Banuelos, Yu-Chi Yang
-
Patent number: 11918562Abstract: Provided is a novel method for treating cancer using an HSP90 inhibitor which exhibits a markedly superior antitumor effect and has a reduced side effect. An antitumor agent is characterized in that an azabicyclo compound of the following Formula (1) or a salt thereof is administered in combination with other antitumor agent(s).Type: GrantFiled: September 30, 2021Date of Patent: March 5, 2024Assignee: TAIHO PHARMACEUTICAL CO., LTD.Inventors: Hiromi Muraoka, Akira Kanoh
-
Patent number: 11911744Abstract: Provided are superabsorbent materials composed of agar, and one or more water-soluble natural polysaccharides, and dietary compositions containing such superabsorbent materials. The disclosed superabsorbent materials have various food and therapeutic applications and can be used as loading vehicles for nutrients and therapeutic agents. Also provided are methods for preparing such superabsorbent materials.Type: GrantFiled: June 4, 2021Date of Patent: February 27, 2024Inventor: Lijun Sun
-
Patent number: 11912983Abstract: The present technology relates to a method of separating a sample comprising oligonucleotides. The method includes injecting a polyphosphonic acid at a concentration of between about 0.01 M to about 1 M into the sample comprising oligonucleotides. The method also includes flowing the sample and polyphosphonic acid through a liquid chromatography column and separating the oligonucleotides.Type: GrantFiled: December 4, 2020Date of Patent: February 27, 2024Assignee: Waters Technologies CorporationInventors: Michael Donegan, Martin Gilar, Matthew Lauber, Scott Mccall, Pamela Iraneta, Kerri Smith
-
Patent number: 11912731Abstract: The present invention relates to a method for preparing organic compounds of formula (I) by reaction between a silylated formiate of formula (II) and an organic compound in the presence of a catalyst and optionally of an additive. The invention also relates to use of the method for preparing organic compounds of formula (I) for the preparation of reagents for fine chemistry and for heavy chemistry, as well as in the production of vitamins, pharmaceutical products, adhesives, acrylic fibres, synthetic leathers, and pesticides.Type: GrantFiled: August 7, 2017Date of Patent: February 27, 2024Assignee: Commissariat a l'Energie Atomique et aux Energies AlternativesInventors: Clément Chauvier, Thibault Cantat, Timothé Godou
-
Patent number: 11884779Abstract: A hydrophilic silicone, compositions comprising the same, and articles comprising the same are shown and described herein. The hydrophilic silicone is an ionically modified silicone compound wherein the compound comprises a zwitterionic moiety and has a net neutral charge. The hydrophilic silicone compounds may be provided as part of a composition, e.g., a composition suitable for forming a hydrogel, which may be employed to form a film material and even an article (e.g., in a contact lens).Type: GrantFiled: February 16, 2018Date of Patent: January 30, 2024Assignee: Momentive Performance Materials Inc.Inventors: Sukanta Dolai, Shreedhar Bhat, Meenal Mehra
-
Patent number: 11884647Abstract: The disclosure provides compounds, and compositions, including pharmaceutical compositions, kits that include the compounds, and methods of using (or administering) and making the compounds. The disclosure further provides compounds or compositions thereof for use in a method of modulating PLXDC1 (TEM7) and/or PLXDC2 or killing pathogenic blood vessles. The disclosure further provides compounds or compositions thereof for use in a method of treating a disease, disorder, or condition that is mediated, at least in part, by PEDF receptors or by angiogenesis.Type: GrantFiled: October 16, 2020Date of Patent: January 30, 2024Assignees: The Regents of the University of California, Atengen, Inc.Inventors: Hui Sun, Pu Sun, Guo Cheng, Adrian Chichuen Au, Ming Zhong
-
Patent number: 11883425Abstract: The invention provides compositions and methods to treat diabetes with improved formulations in which metformin is combined with at least three antioxidants that contain a stabilizing heteroatom adjacent to a saturated carbon and which help maintain a balance between antioxidant and pro-oxidant properties. The antioxidants include at least the combination of taurine, citrulline and methylcobalamin, and optionally include melatonin. The composition provides management of blood glucose levels comparable to metformin in the same dose without antioxidants, without the phenomenon of undermining metformin performance that is commonly observed in the presence of co-administered antioxidants.Type: GrantFiled: April 18, 2022Date of Patent: January 30, 2024Inventor: William H. Cross, III